Association of Alopecia Areata With COVID-19 Vaccination: A Vaccine Adverse Events Reporting System Analysis

This study examined 206 cases of alopecia areata (AA) reported in the Vaccine Adverse Events Reporting System (VAERS) after COVID-19 vaccination in the U.S., with most cases occurring in females (66%) and a mean age of 41.4 years. AA was commonly observed within 1 month post-vaccination, especially in the 18-39 age group. No significant difference in AA risk was found between vaccine manufacturers, though Pfizer had a higher proportion of cases. A history of autoimmune disorders or previous vaccination adverse events did not significantly increase AA risk. The study indicates a potential association between AA and COVID-19 vaccination, emphasizing the need for further research to explore the mechanisms and develop management strategies.